All In Biotech

Drug Trial Radar · NCT03964233

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 (Brigimadlin) With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 (Brigimadlin) With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

119

Actual

Start

Jun 20, 2019

Primary completion

Sep 5, 2024

Study completion Feb 6, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has 2 parts. The first part of the study is done. The first part was open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts. The participants get a combination of 2 medicines called brigimadlin (also called BI 907828) and ezabenlimab (also called BI 754091). Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). When the study started, some participants got a third medicine called BI 754111 in addition. Treatment with BI 754111 was stopped because data from another study showed no additional effect of BI 754111. The purpose of the first part of the study was to find out the highest dose of brigimadlin that the participants could tolerate in combination with ezabenlimab. This dose is used in the second part of the study. The purpose of the second part is to see whether the combination of brigimadlin with ezabenlimab is able to make tumors shrink. The participants are in the study as long as they benefit from treatment and can tolerate it. Ezabenlimab treatment is limited to 2 years. During this time, they get infusions of ezabenlimab, and take tablets with brigimadlin every 3 weeks. The doctors check how many participants have health problems during the study. The doctors also monitor the size of the tumor.

Conditions

  • Neoplasms

Interventions

  • BI 907828Drug

    Film-coated tablets

  • ezabenlimabDrug

    Solution for infusion

  • BI 754111Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia - maximum tolerated dose (MTD) of brigimadlin (BI 907828) in combination with ezabenlimab based on the number of patients with dose limiting toxicities (DLTs) during the first treatment cycleTime frame: Up to 21 Days
  2. Phase Ib - Objective response (OR)Time frame: Up to 24 months
  3. Phase Ib - Progression free survivalTime frame: Up to 24 months

Locations

23 sites in 11 countries. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • University Cancer and Blood Center

    Athens, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology-Irving-69444

    Irving, Texas

  • NEXT Oncology-San Antonio-65273

    San Antonio, Texas

  • NEXT Virginia

    Fairfax, Virginia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • UZ Leuven

    Leuven, Belgium

  • INS Bergonie

    Bordeaux, France

  • CTR Leon Berard

    Lyon, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Central Hospital of Northern Pest - Military Hospital

    Budapest, Hungary

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • The Royal Marsden Hospital, Chelsea

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.